Evidence map›Paper›PMID 28941311›Full record

ArticleClinical endocrinology2018

Endocrinopathies with use of cancer immunotherapies.

Natalie M Villa, Abtin Farahmand, Lin Du, Michael W Yeh, Stephanie Smooke-Praw, Antoni Ribas, Bartosz Chmielowski, Grace Cherry, Angela M Leung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Natalie M VillaUCLA David Geffen School of Medicine, Los Angeles, CA, USA.ORCID 0000-0002-0366-3155
Abtin FarahmandDepartment of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Lin DuDepartment of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Michael W YehSection of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Stephanie Smooke-PrawDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Antoni RibasDivision of Hematology and Oncology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Bartosz ChmielowskiDivision of Hematology and Oncology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Grace CherryDivision of Hematology and Oncology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Angela M LeungDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
University of California, Los Angeles · USUCLA Health · US

Funding

Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
Iodine Nutrition and Thyroid Disease During Pregnancy and LactationK23HD068552 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LEUNG, ANGELA MEI-TIN · 2011 to 2015
$644k
NCI NIH HHS R35 CA197633NICHD NIH HHS K23 HD068552
6 · The paper itself

Abstract

backgroundImmunomodulatory therapies, including CTLA-4 and PD-1 inhibitors, provide a directed attack against cancer cells by preventing T cell deactivation. However, these drugs also prevent the downregulation of auto-reactive T cells, resulting in immune-related adverse events (IRAEs). Reports show a varied incidence of endocrine IRAEs, ranging from 0% to 63%.

objectiveTo describe the frequency and clinical characteristics of endocrine IRAEs in patients taking cancer immunomodulatory therapies.

designRetrospective cohort study. PATIENTS: A total of 388 patients aged ≥18 years who were prescribed ipilimumab, nivolumab and/or pembrolizumab between 2009 and 2016 at our institution. MEASUREMENTS: Biochemical criteria were used to define endocrine IRAEs, including thyroid, pituitary, pancreas and adrenal dysfunction, following use of immunomodulatory therapies.

resultsFifty endocrine IRAEs occurred in our cohort, corresponding to a rate of 12.9%. The most common endocrine IRAEs were thyroid dysfunction (11.1%), with a lower incidence of pituitary dysfunction (1.8% of patients).

conclusionsOver 12% of patients receiving ipilimumab, nivolumab and/or pembrolizumab in our study sample developed an endocrine IRAE. Patients who undergo treatment with immunomodulatory therapies should be monitored for the development of endocrine IRAEs.

Indexed as

AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCTLA-4 AntigenEndocrine System DiseasesFemaleHumansHypothyroidismImmunotherapyIpilimumabMaleMiddle AgedNivolumabProgrammed Cell Death 1 ReceptorRetrospective StudiesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCTLA-4 AntigenCTLA4 protein, humanIpilimumabNivolumabpembrolizumabProgrammed Cell Death 1 Receptorhyperthyroidismhypopituitarismthyroiditis

Identifiers

PMID28941311
PMCPMC5771947
OpenAlexW2758551515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.